Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety and Tolerability Study of an Edible Colon Preparation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02402270
Recruitment Status : Completed
First Posted : March 30, 2015
Last Update Posted : January 29, 2018
Information provided by (Responsible Party):
ColonaryConcepts LLC

Brief Summary:

The purpose of this study is to learn about a new bowel preparation that uses food to clean the colon.

In order to learn about this new food preparation, some people in this study will get the food preparation, and others will get the standard liquid bowel preparation.

Patients will be randomized (like flipping a coin) to one of five groups:

Group 1 - Menu A Meal Kit - contains bars, shakes, soup, and a rice bowl Group 2 - Menu B Meal Kit - contains bars, shakes, soup, and a rice bowl Group 3 - Menu C Meal Kit - contains bars and shakes Group 4 - MoviPrep Group 5 - NuLYTELY

Condition or disease Intervention/treatment Phase
Bowel Preparation Drug: NuLYTELY® (PEG 3350) Drug: ECP-019 Drug: MoviPrep® (PEG 3350) Phase 2

Detailed Description:
The purpose of this Phase 2 formulation screening/proof of concept study is to evaluate the safety, tolerability, and efficacy of up to 3 ECP-019 formulations/dosing regimens comprising a PEG 3350 Colon Prep Kit, containing electrolytes provided by the foods, in 3 formulations/ dosing regimens as compared to 2 comparators in a Phase 2 study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Other
Official Title: An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.
Actual Study Start Date : May 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: ECP-019 A (Group A) Drug: ECP-019
Experimental: ECP-019 B (Group B) Drug: ECP-019
Experimental: ECP-019 C (Group C) Drug: ECP-019
Active Comparator: Group D Drug: MoviPrep® (PEG 3350)
Active Comparator: Group E Drug: NuLYTELY® (PEG 3350)

Primary Outcome Measures :
  1. The proportion of patients with successful colon cleansing as assessed by the blinded gastroenterologists using the Aronchick Scale. [ Time Frame: One year ]

Secondary Outcome Measures :
  1. Percentage of patients who completed each of the ECP-019 formulation/dosing regimens [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients whose physician has prescribed colonoscopy for colorectal cancer screening or surveillance for colorectal cancer.
  • Patients with a previous history of completing a bowel cleansing procedure for a colonoscopy.

Exclusion Criteria:

  • Known intestinal stricture of any etiology.
  • History of diabetes mellitus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02402270

Layout table for location information
United States, Indiana
Indianapolis, Indiana, United States, 46290
United States, New Hampshire
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
ColonaryConcepts LLC
Layout table for additonal information
Responsible Party: ColonaryConcepts LLC Identifier: NCT02402270    
Other Study ID Numbers: ECP-002
First Posted: March 30, 2015    Key Record Dates
Last Update Posted: January 29, 2018
Last Verified: January 2018
Keywords provided by ColonaryConcepts LLC:
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyethylene glycol 3350
Gastrointestinal Agents